ArticleFrontiers in nutrition2025
Investigating the impact of aspartame on Alzheimer's disease through network toxicology and molecular docking.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial Sweeteners and Autoimmune Diseases: Insights From Integrative Bioinformatics and Mendelian Randomization.Food science & nutrition · 2026Article
- Unraveling the anti-neuroinflammatory mechanisms of Cervus cucumis polypeptide injection in Alzheimer's disease: insights from network pharmacology, molecular docking, molecular dynamics simulation, and experimental validation.Frontiers in aging neuroscience · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Alzheimer's disease (AD) is a prevalent neurodegenerative disorder, and the relationship between its pathogenesis and environmental factors has garnered increasing scholarly interest. Aspartame, a widely utilized artificial sweetener, has potential neurotoxic effects that remain incompletely understood. This study employs network toxicology and molecular docking to speculate on the potential molecular mechanisms by which aspartame is involved in the pathological process of AD. Methods: By integrating data from multiple databases, including ChEMBL, SwissTargetPrediction, OMIM, and GeneCards, we obtained the shared targets of aspartame and AD. A protein-protein interaction (PPI) network was constructed using the STRING database and Cytoscape software to discern the core targets. Subsequently, Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analyses were performed via the DAVID database, and molecular docking validation of the core targets was conducted using AutoDock Vina. Results: In this study, a total of 298 targets associated with aspartame and 2,042 targets related to AD were identified. Seventy-five common targets were discovered, with BCL2, PPARG, TNF, IL1β, MAPK3, ESR1, and CASP3 were hypothesized as key core targets. GO functional analysis indicated that these targets are predominantly involved in biological processes such as protein metabolism, neuroinflammation, apoptosis, and oxidative stress. Furthermore, KEGG pathway analysis revealed significant enrichment in pathways TNF signaling, MAPK signaling, and PI3K-Akt signaling, among others. Molecular docking studies have shown that aspartame has A certain binding affinity with some core targets. Discussion: It is speculated that aspartame may be involved in the key pathological processes of AD through multi-target and multi-pathway mechanisms, including neuroinflammation, apoptosis and amyloid-beta (Aβ) metabolism. This computational study speculates that aspartame, as an environmental exposure factor, is involved in the potential molecular mechanism of AD pathogenesis, thereby providing a theoretical basis for evaluating its neurotoxicity. Further experimental studies are needed in the future to confirm its biological effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.